Access Pharmaceuticals, Inc. 

(Public, OTC:ACCP)   Watch this stock   
Find more results for ACCP

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -3504.76% -5915.81%
Operating margin -3320.64% -5812.72%
EBITD margin - -5725.77%
Return on average assets -296.44% -256.83%
Return on average equity - -
Employees 9 -

Address

2600 Stemmons Freeway Suite 176
Dallas, TX 75207
United States - Map
+1-214-9055100 (Phone)
+1-214-9055101 (Fax)

Website links

Access Pharmaceuticals, Inc. discussions

  View all discussions »

Description

Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

Officers and directors

Steven H. Rouhandeh
Chairman of the Board
Age: 51
Jeffrey B. Davis
Chief Executive Officer, Director
Age: 46
Stephen B. Thompson
Chief Financial Officer, Vice President, Treasurer, Secretary
Age: 55
Esteban Cvitkovic M.D.
Vice Chairman (Europe), Director
Age: 59
David P. Nowotnik Ph.D.
Senior Vice President - Research and Development
Age: 60
Phillip S. Wise
Vice President - Business Development and Strategy
Age: 50
Stephen B. Howell M.D.
Director
Age: 64
Mark J. Alvino
Director
Age: 41
Mark J. Ahn Ph.D.
Director
Age: 46
David P. Luci
Director
Age: 42